Funding Momentum PAQ Therapeutics has secured substantial funding including a $77M Series B in 2026 and a $30M Series A in 2021, signaling strong investor confidence and runway to advance KRAS ATTEC degrader programs which could open opportunities for strategic partners, CROs, and co-development collaborations.

KRAS Focus The current investor-led round explicitly targets KRAS-targeting drug candidates in Phase I for advanced solid tumors, presenting a clear sales and collaboration angle with firms seeking oncology autophagy-based degradation therapies, biomarker partners, and companion diagnostic developers.

Autophagy Platform PAQ’s ATTEC technology enables degradation of diverse substrates via autophagy, offering a broad collaboration landscape with drug discovery platforms, AI-driven discovery partners, and contract research organizations interested in expanding small molecule degradation capabilities.

Strategic Partnerships Ongoing collaborations with Insilico Medicine emphasize AI-driven drug discovery and integrated chemistry platforms, suggesting potential for expanded co-development deals, data-sharing agreements, and joint optimization programs with AI and computational chemistry providers.

Growth Readiness Despite a small headcount, PAQ has demonstrated rapid expansion financing and a robust pipeline; this positions the company as a suitable candidate for strategic alliances with larger biotech or pharma firms seeking to accelerate autophagy-based therapies and to leverage PAQ’s early-stage assets in gut-check markets and translational programs.